Tags Archive Navigation
icon
-
Media ReleaseNovartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
-
Media ReleaseNovartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
-
Media ReleaseNew Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancer
-
Media ReleaseNew CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer
-
Media ReleaseFDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
-
Media ReleaseNovartis provides update on production of radioligand therapy medicines
-
Media ReleaseNovartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host disease
-
Media ReleaseNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
-
Media ReleaseNovartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
-
Media ReleaseNovartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 10
- › Next page